Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Oxford BioMedica ( (GB:OXB) ) is now available.
Oxford Biomedica announced that Natalie Walter, Group General Counsel and Company Secretary, exercised 28,321 LTIP options and 39,679 DBP options, subsequently selling 68,000 shares at an average price of £6.116876 per share. This transaction, conducted on the London Stock Exchange, reflects the company’s adherence to EU Market Abuse Regulation requirements and highlights the ongoing financial activities of its senior management.
The most recent analyst rating on (GB:OXB) stock is a Buy with a £970.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Spark’s Take on GB:OXB Stock
According to Spark, TipRanks’ AI Analyst, GB:OXB is a Neutral.
Oxford BioMedica’s overall score reflects strong earnings call insights and positive corporate events, indicating strategic growth and leadership confidence. However, financial performance challenges and valuation concerns moderate the score.
To see Spark’s full report on GB:OXB stock, click here.
More about Oxford BioMedica
Oxford Biomedica (OXB) is a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapy. With 30 years of experience, OXB is a pioneer in viral vectors, collaborating with leading pharmaceutical and biotechnology companies. The company offers expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vector types, supporting clients from early-stage development to commercialization. OXB is headquartered in Oxford, UK, with facilities in the UK, France, and the US.
Average Trading Volume: 255,635
Technical Sentiment Signal: Buy
Current Market Cap: £777.7M
See more data about OXB stock on TipRanks’ Stock Analysis page.